press release: (OVA1) Vermillion Receives Notice of Allowance for Patent of Biomarker for Ovarian Cancer Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Monday, April 16, 2012

press release: (OVA1) Vermillion Receives Notice of Allowance for Patent of Biomarker for Ovarian Cancer



Vermillion Receives Notice of Allowance for Patent of Biomarker for Ovarian Cancer


(press release) About OVA1
OVA1 is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using a unique multi-biomarker approach. In a published clinical trial, OVA1 achieved 99% sensitivity in detecting epithelial ovarian cancers (EOC). This included 96% sensitivity for stage I EOC, the earliest and most curable EOC stage, compared with 57% for the conventional biomarker CA125.(1) In addition, OVA1 found 70% of malignancies missed by non-specialist pre-surgical assessment,(1) and it increased detection of malignancy over ACOG guidelines from 77% to 94%.(2) As the first protein-based, In Vitro Diagnostic Multi-Variate Index Assay (IVDMIA) cleared by the FDA, OVA1 also represents a new class of software-based diagnostics.

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.